• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's After-Market Session

    10/31/23 5:31:12 PM ET
    $AMTI
    $BWV
    $DRIO
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMTI alert in real time by email

    Gainers

    • Plus Therapeutics (NASDAQ:PSTV) shares rose 20.3% to $1.48 during Tuesday's after-market session. Today's trading volume for this security ended up closing at 1.0 million shares, which is 236.3 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $4.2 million. The company's, Q3 earnings came out today.
    • NewAmsterdam Pharma (NASDAQ:NAMS) shares increased by 11.11% to $10.0. The company's market cap stands at $823.2 million.
    • China SXT Pharmaceuticals (NASDAQ:SXTC) shares increased by 10.23% to $2.37. The company's market cap stands at $1.3 million.
    • DarioHealth (NASDAQ:DRIO) stock moved upwards by 7.81% to $1.38. The market value of their outstanding shares is at $37.5 million.
    • Pluri (NASDAQ:PLUR) shares moved upwards by 7.75% to $0.55. The company's market cap stands at $22.5 million.
    • Oncology Institute (NASDAQ:TOI) shares moved upwards by 7.32% to $2.05. The company's market cap stands at $149.5 million.

    Losers

    • Alaunos Therapeutics (NASDAQ:TCRT) shares declined by 7.9% to $0.07 during Tuesday's after-market session. Alaunos Therapeutics's trading volume hit 388.2K shares by close, accounting for 14.0% of its average volume over the last 100 days. The market value of their outstanding shares is at $17.7 million.
    • Blue Water Biotech (NASDAQ:BWV) shares declined by 7.44% to $0.36. The company's market cap stands at $6.4 million.
    • Vaccitech (NASDAQ:VACC) shares declined by 6.32% to $3.93. The company's market cap stands at $151.6 million.
    • Onconova Therapeutics (NASDAQ:ONTX) stock decreased by 5.99% to $0.6. The market value of their outstanding shares is at $12.6 million.
    • Applied Molecular (NASDAQ:AMTI) shares decreased by 5.6% to $0.14. Today's trading volume for this security ended up closing at 115.0K shares, which is 10.3 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $5.3 million.
    • NeuroBo Pharmaceuticals (NASDAQ:NRBO) stock declined by 5.55% to $0.41. The market value of their outstanding shares is at $15.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AMTI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMTI
    $BWV
    $DRIO
    $NAMS

    CompanyDatePrice TargetRatingAnalyst
    NewAmsterdam Pharma Company N.V.
    $NAMS
    3/18/2026$57.00Buy
    Truist
    PLUS THERAPEUTICS Inc.
    $PSTV
    2/3/2026$2.00Buy
    Lake Street
    The Oncology Institute Inc.
    $TOI
    11/25/2025$5.00Buy
    Needham
    NewAmsterdam Pharma Company N.V.
    $NAMS
    10/20/2025$52.00Buy
    H.C. Wainwright
    PLUS THERAPEUTICS Inc.
    $PSTV
    9/3/2025$5.00Hold → Buy
    D. Boral Capital
    NewAmsterdam Pharma Company N.V.
    $NAMS
    8/25/2025$45.00Overweight
    Wells Fargo
    The Oncology Institute Inc.
    $TOI
    7/23/2025$8.00Outperform
    Noble Capital Markets
    NewAmsterdam Pharma Company N.V.
    $NAMS
    7/17/2025$27.00Neutral
    Goldman
    More analyst ratings

    $AMTI
    $BWV
    $DRIO
    $NAMS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chernett Jorey

    4 - Oncology Institute, Inc. (0001799191) (Issuer)

    3/27/26 9:34:25 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    SEC Form 4 filed by Chernett Jorey

    4 - Oncology Institute, Inc. (0001799191) (Issuer)

    3/25/26 9:33:09 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    SEC Form 4 filed by Chernett Jorey

    4 - Oncology Institute, Inc. (0001799191) (Issuer)

    3/23/26 9:33:11 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    $AMTI
    $BWV
    $DRIO
    $NAMS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Chernett Jorey bought $1,225,101 worth of shares (398,985 units at $3.07), increasing direct ownership by 4% to 10,251,929 units (SEC Form 4)

    4 - Oncology Institute, Inc. (0001799191) (Issuer)

    3/17/26 7:40:00 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    Director Manieu Alexandre Weinstein was granted 10,250 shares, exercised 1,002,169 shares at a strike of $0.00 and bought $2,086,956 worth of shares (452,702 units at $4.61) (SEC Form 4)

    4 - Pluri Inc. (0001158780) (Issuer)

    11/20/25 11:35:50 AM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Sims Andrew John Hugh Macintyre bought $10,200 worth of shares (20,000 units at $0.51), increasing direct ownership by 42% to 68,138 units (SEC Form 4)

    4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)

    11/5/25 8:30:03 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $AMTI
    $BWV
    $DRIO
    $NAMS
    SEC Filings

    View All

    Pluri Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - Pluri Inc. (0001158780) (Filer)

    3/27/26 6:33:11 AM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    PLUS THERAPEUTICS Inc. filed SEC Form 8-K: Leadership Update

    8-K - PLUS THERAPEUTICS, INC. (0001095981) (Filer)

    3/26/26 8:33:06 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 filed by DarioHealth Corp.

    S-8 - DarioHealth Corp. (0001533998) (Filer)

    3/19/26 5:03:14 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $AMTI
    $BWV
    $DRIO
    $NAMS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pluri Secures Additional Investment from Chairman Alejandro Weinstein at 30% Premium to Market in a Private Placement

    HAIFA, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. ("Pluri" or the "Company") (Nasdaq, TASE: PLUR), a biotechnology company leveraging a proprietary cell-based platform across multiple commercial verticals, today announced that an entity beneficially owned by Alejandro Weinstein, Chairman of the Board and one of the Company's largest shareholders, has entered into a Securities Purchase Agreement with Pluri for an additional $2.5 million investment in the Company at a 30% premium to the market price on March 24, 2026. This additional investment follows Mr. Weinstein's prior $2.5 million investment announced in connection with his appointment as Chairman of the Board, and further

    3/26/26 8:30:00 AM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of Directors

    HOUSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announces the appointment of diagnostics industry veteran Ron Andrews to its Board of Directors. "Ron Andrews brings an extensive wealth of diagnostics experience to the Plus board room developed over multiple decades in the industry," said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. "He will make an immediate impact on the Company as we scale CNSide, first in the U.S. and then globally. Furthermore, his bre

    3/26/26 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    China SXT Pharmaceuticals, Inc. Announces Share Re-classification

    TAIZHOU, China, March 23, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceutics, Inc. (NASDAQ:SXTC) (the "Company" or "SXTC"),  a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS"), today announced that upon the market opening on March 24, 2026, the Company's Class A Ordinary Shares will be traded on The Nasdaq Stock Market under the symbol "SXTC". On July 28, 2025, the Company held a special meeting of shareholders (the "Meeting"). At the Meeting

    3/23/26 9:00:00 AM ET
    $SXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMTI
    $BWV
    $DRIO
    $NAMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist initiated coverage on NewAmsterdam Pharma with a new price target

    Truist initiated coverage of NewAmsterdam Pharma with a rating of Buy and set a new price target of $57.00

    3/18/26 3:54:27 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lake Street initiated coverage on Plus Therapeutics with a new price target

    Lake Street initiated coverage of Plus Therapeutics with a rating of Buy and set a new price target of $2.00

    2/3/26 8:52:26 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Needham initiated coverage on The Oncology Institute with a new price target

    Needham initiated coverage of The Oncology Institute with a rating of Buy and set a new price target of $5.00

    11/25/25 8:00:05 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    $AMTI
    $BWV
    $DRIO
    $NAMS
    Leadership Updates

    Live Leadership Updates

    View All

    Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of Directors

    HOUSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announces the appointment of diagnostics industry veteran Ron Andrews to its Board of Directors. "Ron Andrews brings an extensive wealth of diagnostics experience to the Plus board room developed over multiple decades in the industry," said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. "He will make an immediate impact on the Company as we scale CNSide, first in the U.S. and then globally. Furthermore, his bre

    3/26/26 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    The Oncology Institute Appoints Kim Tzoumakas to Board of Directors

    CERRITOS, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced the appointment of Kim Tzoumakas to its Board of Directors, effective February 23, 2026. Ms. Tzoumakas brings more than two decades of executive leadership experience across oncology, pharmacy services and healthcare operations. Notably, she is Chief Executive Officer for VytlOne National Pharmacy Services, and previously held the CEO role at 21st Century Oncology, where she successfully led the organization through a multi-year operational turnaround, culminating in its strategic sale. She also has serve

    2/23/26 8:00:00 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    The Oncology Institute Announces Addition of Board Member Mark Stolper

    CERRITOS, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced that Mark Stolper has joined the Board of Directors, effective January 2, 2026. Mr. Stolper brings significant public markets, financial and operational leadership experience to The Oncology Institute's board. Mr. Stolper serves as Executive Vice President and Chief Financial Officer of RadNet, Inc. (NASDAQ:RDNT), a position he has held since 2004. Mr. Stolper has also been a member of the Board of Directors of various publicly traded and privately held healthcare companies, including 21st Century Oncolog

    1/5/26 8:30:00 AM ET
    $RDNT
    $TOI
    Medical Specialities
    Health Care
    Medical/Nursing Services

    $AMTI
    $BWV
    $DRIO
    $NAMS
    Financials

    Live finance-specific insights

    View All

    Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40%

    HOUSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announces the presentation of a new health economics study evaluating the economic impact of earlier detection and therapeutic management of LM using the CNSide cerebrospinal fluid (CSF) assay. The cost-of-care analysis suggests that earlier LM diagnosis and therapeutic management enabled by CNSide may reduce overall LM-related healthcare costs by approximately 40%, primarily through earlier therapeutic intervention, improved treatment precisio

    3/19/26 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    DarioHealth Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

    Fourth quarter 2025 revenues grew sequentially to $5.2 million as compared to $5.0 million in the third quarter of 20252025 full-year revenue was $22.4 million, compared to $27.0 million in 2024, due entirely to a scope change and nonrenewal from a single legacy client that came through the Twill, Inc. ("Twill") acquisition — unrelated to demand — partially offset by organic revenue growth The 2025 sales season — Dario's strongest on record — generated $12.9 million in contracted and late stage, annual recurring revenue ("ARR")  set to contribute revenue in 2026 and 2027 and position the Company for a high-growth trajectoryGAAP gross margins increased to 57% in 2025 from 49% in 2024 and Non-

    3/19/26 6:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    The Oncology Institute Reports Fourth Quarter and Full Year 2025 Financial Results and Guidance for 2026

    CERRITOS, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its fourth quarter and year ended December 31, 2025. Recent Operational Highlights Cash flow from operations in Q4 2025 was approximately $3.2 million, due to disciplined working capital management and overall increase in gross profit marginContinued expansion of our capitated footprint, initiating 9 new capitated contracts during 2025 in CA, FL, and NV, representing approximately 260,000 additional lives under managementFurther ramped our capitation

    3/12/26 4:05:00 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    $AMTI
    $BWV
    $DRIO
    $NAMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by NewAmsterdam Pharma Company N.V.

    SC 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

    12/17/24 5:35:24 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by NewAmsterdam Pharma Company N.V.

    SC 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

    12/17/24 4:00:47 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by NewAmsterdam Pharma Company N.V.

    SC 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

    12/17/24 10:28:58 AM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care